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Abstract
Background: Uremic cardiomyopathy contributes substantially to mortality in chronic kidney disease (CKD) patients.
Glucagon-like peptide-1 (GLP-1) may improve cardiac function, but is mainly degraded by dipeptidyl peptidase-4 (DPP-4).
Methodology/Principal Findings: In a rat model of chronic renal failure, 5/6-nephrectomized [5/6N] rats were treated orally
with DPP-4 inhibitors (linagliptin, sitagliptin, alogliptin) or placebo once daily for 4 days from 8 weeks after surgery, to
identify the most appropriate treatment for cardiac dysfunction associated with CKD. Linagliptin showed no significant
change in blood level AUC(0-‘) in 5/6N rats, but sitagliptin and alogliptin had significantly higher AUC(0-‘) values; 41% and
28% (p=0.0001 and p=0.0324), respectively. No correlation of markers of renal tubular and glomerular function with AUC
was observed for linagliptin, which required no dose adjustment in uremic rats. Linagliptin 7 mmol/kg caused a 2-fold
increase in GLP-1 (AUC 201.0 ng/l*h) in 5/6N rats compared with sham-treated rats (AUC 108.6 ng/l*h) (p=0.01). The mRNA
levels of heart tissue fibrosis markers were all significantly increased in 5/6N vs control rats and reduced/normalized by
linagliptin.
Conclusions/Significance: DPP-4 inhibition increases plasma GLP-1 levels, particularly in uremia, and reduces expression of
cardiac mRNA levels of matrix proteins and B-type natriuretic peptides (BNP). Linagliptin may offer a unique approach for
treating uremic cardiomyopathy in CKD patients, with no need for dose-adjustment.
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Introduction
Chronic kidney disease (CKD) and moreover, end-stage renal
disease (ESRD), have been shown to increase cardiovascular
disease and risk of death [1,2]. This has been substantiated in a
systematic review on mortality risk, which concluded that
increased risk for all-cause mortality in CKD patients was largely
driven by cardiovascular deaths (58% deaths from 13 studies
reporting both cardiovascular and all-cause deaths) [3].
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
secreted by the small intestine in response to nutrient ingestion.
Although the major physiological function of GLP-1 appears to
relate to glycaemic control, evidence suggests that GLP-1 plays an
important role in the cardiovascular system. GLP-1 receptors
(GLP-1Rs) are expressed in the heart and vasculature of rodents as
well as humans. Research has shown that GLP-1R agonists affect
a wide range of cardiovascular parameters, including heart rate,
blood pressure, vascular tone and myocardial contractility.
Importantly, these agents may also have beneficial effects in the
setting of cardiovascular disease (CVD). For example, GLP-1 has
been found to exert cardioprotective actions in experimental
models of dilated cardiomyopathy, hypertensive heart disease and
myocardial infarction (MI). Preliminary clinical studies also
suggest that GLP-1 infusion may improve cardiac contractile
function in chronic heart failure patients with and without
diabetes, and in MI patients after successful angioplasty [4,5,6].
However, the cardiovascular effects of a pharmacological increase
in GLP-1 in patients with CKD have not been determined.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered
incretin enhancers, because they inhibit the enzymatic degrada-
tion of incretins, in particular, GLP-1 [7] and therefore are
established therapies for type 2 diabetes. At the same time, DPP-4
inhibition does not cause hypoglycemia, as was previously shown
by Bergman et al in a study in healthy male volunteers [8].
Because the action of GLP-1 on insulin secretion is strictly glucose
dependent, the risk of hypoglycaemia associated with DPP-4
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27861inhibitors is low [9].The main elimination route of the first
generation of approved DPP-4 inhibitors (sitagliptin, saxagliptin,
vildagliptin) is via the kidney [7,10]. Dose adjustment in patients
with diabetes and chronic renal failure (CRF) is thus necessary
[10,11]. Linagliptin a recently launched DPP-4 inhibitor is
different in this respect with primary elimination via the bile
(approximately 85% of the orally administered dose) and only 1–
5% eliminated via the urine [12,13].
We studied the pharmacokinetics and pharmacodynamics of
different DPP-4 inhibitors, in the settings of CRF, in order to
determine the properties of DPP-4 inhibitors to be used in patients
with impaired renal function, and investigated the effects of
linagliptin on biomarkers of cardiac and renal fibrosis. The results
showed that DPP-4 inhibition increases plasma GLP-1 levels,
particularlyin uremia, suggesting that linagliptin may offer a unique
approach for treating uremic cardiomyopathy in CKD patients.
Results
This study showed that 5/6N caused a significant decrease in
GFR as measured by creatinine clearance and increased plasma
cystatin C levels. Tubular function was significantly impaired after
5/6N as evidenced by increased plasma b2-microglobulin, NGAL
andosteopontinlevels.There was no significantdifferenceinDPP-4
activity in 5/6N rats compared with sham-operated rats before
treatment (Table 1), but DPP-4 activity decreased significantly in all
groups following drug administration with no significant differences
between control or 5/6N groups. The strongest DPP-4 inhibition
wasachievedafteradministrationof7 mmol/kglinagliptin(Table2),
whereas the other groups were comparable. The GLP-1 receptor
mRNA expression was reduced about 40% in uremic rats as
compared to healthy control rats (table 1).
We tested plasma glucose concentrations on alternate days
while the rats were being treated with DPP-4 inhibitors. There was
no change in plasma glucose in rats treated with DPP-4 inhibitors
compared with nontreated animals (data not shown).
Influence of DPP-4 inhibitor administration on
pharmacokinetic parameters in sham-operated rats and
5/6N rats
There were no difference in the blood concentration of linagliptin
0.5 mmol/kg in 5/6N rats (AUC(0-‘) 257.5621.44 nmolNh/l;
p=0.771) compared with sham-operated rats (AUC(0-‘)
267.4628.85 nmolNh/l). A similar effect was seen after administra-
tion of linagliptin 7 mmol/kg in 5/6N rats (AUC(0-‘)
12526372.8 nmolNh/l) compared with sham-operated rats
(AUC(0-‘)7 4 8 674.52 nmolNh/l), with a slight, but not significant
(p=0.283), decrease in AUC levels observed for linagliptin. In
contrast, both sitagliptin and alogliptin (7 mmol/kg) had a signifi-
cantly higher AUC(0-‘) in 5/6N rats compared with sham-operated
rats: 41% and 28% (p=0.0001 and p=0.0324), respectively:
sitagliptin sham-operated rats, AUC(0-‘) 36906103 nmolNh/l; 5/
6N rats, AUC(0-‘)6 2 3 8 6423 nmolNh/l and alogliptin sham-
operated rats, AUC(0-‘)1 7 7 1 6225.5 nmolNh/l; 5/6N rats,
AUC(0-‘)2 4 4 5 6166.6 nmolNh/l) (Table 3).
No correlation of markers of renal tubular and glomerular
function with AUC for linagliptin was observed. In contrast,
sitagliptin AUC significantly correlated with GFR, cystatin C, b2-
microglobulin and NGAL, but not with osteopontin. Alogliptin
Table 1. Characteristics of the model of CRF: kidney function parameters, cardiac histology.
Kidney function parameters Sham-operated rats 5/6 N rats
Endogenous creatinine clearance (ml/24 h/g BW, mean 6 SEM) 4.4561.5 3.2760.1***
Cystatin C (ng/ml, mean 6 SEM) 700635.7 1434677.6***
b2-microglobulin (mg/ml, mean 6 SEM) 20.462.4 33.361.34***
NGAL (ng/ml, mean 6 SEM) 286623 680656.3***
Osteopontin (ng/ml, mean 6 SEM) 33.563.2 56.166.2***
Relative left ventricular weight (left ventricular weight/body weight) (%6 SEM)
Cardiac interstitial fibrosis (% of section 6 SEM)
Myocyte diameter (mm 6 SEM)
GLP-1 receptor mRNA in heart tissue
0.2060.01
2.160.1
11.861.1
1.1260.19
0.2960.03
**
2.560.1
*
17.162.0
**
0.7560.15 ***
DPP-4 activity
(fluorescence units, mean 6 SEM)
84315.7763844.56 80594.2463640.53
Values are given in mean6SEM; sham-operated rats group, 5/6N rats, two-tailed students t-test.
*p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0027861.t001
Table 2. DPP-4 activity.
Control
Linagliptin 0.5 mmol/kg
mean±SEM
Linagliptin 7 mmol/kg
mean±SEM
Sitagliptin 7 mmol/kg
mean±SEM
Alogliptin 7 mmol/kg
mean±SEM
DPP-4 activity 821566
20673
459516
13622
210196
5152
572196
21531
508746
8958
DPP-4 activity was measured 24 h after administration of the respective compounds (N=13–17 per DPP-4 inhibitor group, control N=57; no difference was made
between sham-operated rats and 5/6N groups). All drugs showed a significant inhibition of DPP-4 activity (p,0.001) compared with control.
doi:10.1371/journal.pone.0027861.t002
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and osteopontin (p,0.05), but not with GFR and NGAL (Table 4).
Influence on pharmacodynamic parameters in 5/6N rats
following DPP-4 inhibitor administration
To gain further insight into whether kidney function is changed
in the setting of 5/6N after short-term administration of DPP-4
inhibitors, we investigated the tubular and glomerular markers
following drug administration for 4 days and compared these with
the respective pre-treatment values. Creatinine clearance was not
changed after DPP-4 inhibition, independently of the substance
used for treatment (data not shown). The glomerular marker,
cystatin C, was significantly increased following 4 days of
treatment with alogliptin and unchanged after sitagliptin treat-
ment. Linagliptin showed a trend toward decreasing cystatin C
level. None of the drugs affected NGAL levels. Sitagliptin further
significantly aggravated tubular injury by increasing the concen-
tration of b2-microglobulin. This marker remained unchanged by
the other compounds. At the same time, sitagliptin (7.0 mmol/kg
[p,0.01]), alogliptin (7.0 mmol/kg [p,0.01]) and linagliptin
(0.5 mmol/kg [p,0.001]) significantly reduced the concentration
of osteopontin, a marker of tubular injury and fibrosis. The effect
of the higher dose of linagliptin pointed in the same direction, but
did not reach statistical significance (for details see Table 5).
Influence of linagliptin treatment on gene expression of
left ventricular dysfunction marker, BNP, and of fibrotic
markers in 5/6N rat heart
Based on the pharmacodynamic data described above, we have
selected linagliptin as the most suitable and safest drug for further
efficacy studies in rats. We found a significant increase in mRNA
expression of BNP, TGF-b1, TIMP-1, Col1a1 and Col3a1i n
uremic rat heart compared with sham-operated rat heart (see
Figures. 1, 2). Moreover, treatment of the 5/6N rats for only 4
days with linagliptin (7 mmol/kg) significantly reduced gene
expression of BNP and all investigated fibrosis markers (Figure 1;
5/6N linagliptin 7 mmol/kg) almost to baseline levels of healthy
control rats. Cmax values were significantly (p=0.03) higher for 5/
6N (6.462.6 pg/ml) vs sham animals (3.961.9 pg/ml). No
significant changes in DPP-4 inhibition were detected between
sham and 5/6N animals (data not shown).
Discussion
The overall goal of the present study was to compare the
pharmacokinetic properties of available DPP-4 inhibitors in a rat
model of uremic heart disease and select the optimal compound
based on these data for the first pharmacodynamics analyses of
potential efficacy in this rat model.
We have shown that renal impairment does not affect the
pharmacokinetics of linagliptin, whereas it increases the exposure
of sitagliptin and alogliptin. In the present study, only linagliptin
was found not to further aggravate pathological changes of
glomerular and tubular markers in rats with CRF, suggesting that
it is a safe approach to be used in patients with CRF.
Consequently, linagliptin was also the compound of choice to
investigate further effects on uremic cardiomyopathy. This is of
potential clinical impact, since patients with advanced stages of
renal impairment are characterized by a high overall cardiac
morbidity and mortality.
Our study demonstrated for the first time that short-term
treatment with all DPP-4 inhibitors (linagliptin, sitagliptin and
Table 3. AUC of different DPP-4 inhibitors in sham-operated rats vs 5/6N rats.
Treatment
Sham-operated rats, (AUC(0-‘)), nmolNh/l
mean±SEM
5/6N rats (AUC(0-‘)), nmolNh/l
mean±SEM
Alogliptin 7 mmol/kg 17716225.5 24456166.6 *
Linagliptin 0.5 mmol/kg 267.4628.85 257.5621.44
Linagliptin 7 mmol/kg 12526378.8 748.2674.52
Sitagliptin 7 mmol/kg 36906103 62386423 ***
N=5–6 sham-operated rats and 8–13 5/6N rats.
*p,0.05,
***p,0.001.
doi:10.1371/journal.pone.0027861.t003
Table 4. Correlation between AUC of different DPP-4 inhibitors and kidney function parameters in 5/6N rats.
Kidney function parameters
Alogliptin7
mmol/kg, r
2
Sitagliptin
7 mmol/kg, r
2
Linagliptin0.5
mmol/kg, r
2
Linagliptin
7 mmol/kg, r
2
GFR 0.211 0.374* 0.098 0.18
Cystatin C 0.376* 0.499** 0.004 0.189
b2-microglobulin 0.391* 0.543** 0.001 0.092
NGAL 0.295 0.604** 0.091 0.1
Osteopontin 0.406* 0.325 0.005 0.154
Correlation analysis between DPP-4 inhibitors and kidney function parameters was performed using Spearman’s rank correlation test. N=6–12 per group.
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0027861.t004
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calcification marker, osteopontin (Table 5). This suggests a class
effect also, because among all biomarkers investigated only
osteopontin was consistently reduced by DPP-4 inhibitors. The
effect did not reach significance in the higher dose of linagliptin,
most likely due to the high variability of osteopontin data in this
group, however, also those data point towards reduced oster-
opontin levels.
Osteopontin is known to be associated with vascular calcifica-
tion and cardiovascular morbidity in humans [14]. It would be of
major clinical interest to see whether the osteopontin lowering
effect of DPP4 inhibitors can be seen likewise in the ongoing
clinical trials using compounds of this new class.
In addition, linagliptin administration decreased cardiac mRNA
levels of BNP—a marker of left ventricular dysfunction (Figure 1),
and reduced cardiac mRNA expression of fibrosis markers, such as
TGF-b1, TIMP-1, Col1a1 and Col3a1 in uremic rats (Figure 2) to
baseline levels.
The 5/6N rat model of CRF with elimination of two-thirds of
the left kidney after previous right nephrectomy is a gold standard
for the study of CKD. Its pathological characteristics resemble
those of renal failure in humans [15] and are widely used for
investigation of pharmacokinetics of different compounds in the
setting of renal impairment [16,17].
We have shown a simultaneous increase in plasma concentra-
tion of both renally-eliminated DPP-4 inhibitors (sitagliptin and
alogliptin) and markers of glomerular and tubular injury (Table 4).
Only the AUC of linagliptin remained unchanged in the setting of
CRF, which strongly suggests that linagliptin is the only DPP-4
inhibitor that does not require dose adjustment in patients with
CRF.
Investigating the influence of DPP-4 inhibition on kidney
function, we revealed that treatment of rats with DPP-4 inhibitors
does not influence GFR, a finding that agrees with the work of
Kirino et al. [18], who showed no significant differences in serum
creatinine and creatinine clearance levels between wild-type and
DPP-4-deficient mice. Cystatin C was previously shown as a more
sensitive and more efficient diagnostic marker of kidney function
compared with serum creatinine [19,20,21]. Plasma cystatin C
level was increased in rats treated with alogliptin (Table 5),
suggesting that alogliptin administration caused a deterioration in
kidney function, and administration of sitagliptin caused a
significant increase in the concentration of the tubular injury
marker, b2-microglobulin, in 5/6N rats. Only linagliptin admin-
istration did not further aggravate a decline in kidney function in
5/6N rats, suggesting that it is a safe medication to be
administered in the settings of CKD.
It is well known that 5/6N leads to uremic cardiomyopathy
[22,23,24], where transforming growth factor b (TGF-b), tissue
inhibitor of matrix metalloproteinases (TIMP-1) and collagen
(Col3a1) are increased in the uremic heart [25,26,27]. Inhibitors
of these factors have antifibrotic properties, and ameliorate
pathologic changes in the heart in the CRF setting [26,27].
DPP-4 was previously reported as one of the factors that promotes
tissue fibrosis [28]; we have shown that all investigated DPP-4
inhibitors (linagliptin, sitagliptin and alogliptin) decrease plasma
concentrations of the fibrosis marker, osteopontin (Table 5), which
has recently been called ‘‘the killer of patients with CKD’’ [29],
due to its role in vascular calcification. A link between diabetes,
DPP-4 inhibitors and osteopontin was described by Senkel et al. in
their study on hepatocyte nuclear factor 1b (HNF1b) [30]; the
HNF1b promoted gene expression of both targets DPP-4 and
osteopontin. In light of these data, it is of interest that short-term
treatment of uremic rats with the DPP-4 inhibitor, linagliptin,
normalizes the mRNA expression of all of the key factors of uremic
cardiomyopathy (transforming growth factor b (TGF-b), tissue
inhibitor of matrix metalloproteinases (TIMP-1) and collagen
(Col3a1) to baseline level (Figure 2).
Previous studies have already reported a link between DPP-4
inhibition and improvement in cardiac function. DPP-4-deficient
rats had a better preservation of cardiovascular function than wild-
type rats during endotoxemia, which correlated with a more
prominent elevation of GLP-1 signaling. These findings coincided
with the pretreatment of the GLP-1 analogue, exendin-4, where
the deterioration of cardiovascular function during endotoxemia
was significantly reversed in wild-type rats [31]. Elevation of GLP-
1 by DPP-4 inhibitors may have emerging cardiovascular effects in
uremic heart disease.
Baseline GLP-1 concentrations in non-fasted rats with and
without renal failure are low and almost similar (Figure 3).
Table 5. Effects of the different DPP-4 inhibitors on markers of kidney function before and after drug administration in 5/6N rats.
Treatment Condition
Cystatin C [ng/ml]
mean±SEM
b2-microglobulin [mg/ml]
mean±SEM
NGAL [ng/ml]
mean±SEM
Osteopontin
[ng/ml] mean±SEM
Alogliptin 7.0 mmol/kg before 1015.7680.1 32.561.5 473.8668.5 50.965.5
after 1190.36103.7* 32.362.2 520.4658.3 39.168.8**
Linagliptin
0.5 mmol/kg
before 1731.1653.4 35.261.6 921.06117.6 70.964.7
after 1564.4660.6 30.361.5 821.2653.1 48.163.8***
Linagliptin
7.0 mmol/kg
before 1633.66177.9 34.263.9 753.5691.7 54.2610.0
after 1613.36180.7 36.865.2 804.06128.8 49.4610.7
Sitagliptin
7.0 mmol/kg
before 1192.0671.5 30.460.9 490.3693.7 48.564.4
after 1233.66105.6 39.763.8* 1394.56397.4 33.462.4**
Indicated kidney markers were analyzed in blood before and after (4 days + 72 h) DPP-4 inhibitor administration in 5/6N rats. (N= 4–6 in sham-operated rats and 6–12
in 5/6N rats).
*p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0027861.t005
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increase in GLP-1 (AUC 201.0 ng/l*h) in 5/6N rats compared
with sham-treated rats (AUC 108.6 ng/l*h) (p=0.01). These
findings are in line with a recent clinical study [32]. The better
efficacy of the DPP-4 inhibitor, linagliptin, in uremic rats with
respect to plasma GLP-1 concentrations has two implications:
a) DPP-4 inhibition as novel treatment of T2D in patients with
impaired renal function might be particularly effective. In
patients with normal kidney function, treatment with DPP-4
inhibitors usually results in somewhat less pronounced
elevation of GLP-1 as compared with the direct administra-
tion of synthetic GLP-1 [33]; however, this hypothesis needs
to be tested in further clinical trials.
b) The pronounced elevation of GLP-1 after treatment with
linagliptin in uremic rats might contribute to the remarkable
effects of linagliptin on cardiac matrix synthesis via direct
cardiac GLP-1 receptor mediated effects. However, it needs
to be considered that cardiac GLP-1 receptor mRNA
expression was lower in uremic rats (table 1) as compared
to wild type rats. Our data with respect to the plasma
biomarker osteopontin (table 5) as well as the cardiac mRNA
expression of BNP and fibrosis biomarkers (figures 1 and 2)
seem to indicate that the net effect of GLP-1 elevation after
DPP4 inhibition with Linagliptin results in cardio-protection.
However, this needs to be proven in long-term studies (see
also study limitation section below).
Figure 1. Experimental design.
doi:10.1371/journal.pone.0027861.g001
Figure 2. mRNA expression of BNP in uremic rat heart. Gene expression of the marker of left ventricular dysfunction BNP was significantly
increased in rats after initiation of uremia. Treatment with linagliptin at a dose of 7 mmol/kg significantly reduced mRNA expression of BNP in uremic
rat heart. Values are given in mean 6 SEM. N=7 sham-operated rats, 5 5/6N rats and 12 5/6N linagliptin-treated rats. *p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0027861.g002
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inhibition on blood GLP-1 concentrations under the condition of
impaired kidney function is most likely related to the renal
clearance of GLP-1, which is impaired in renal failure, and the
concomitant inhibition of its degradation by DPP-4. This
hypothesis needs to be confirmed by controlled studies that would
investigate the influence of active and total GLP-1 in healthy and
renal-insufficient animals treated with DPP-4 inhibitors.
Although the major physiological function of GLP-1 appears to
be in relation to glycemic control, there is growing evidence to
suggest that it plays an important role in the cardiovascular system
[6]. GLP-1 receptors (GLP-1Rs) are expressed in the heart and
vasculature, and recent studies have shown that GLP-1 receptor
agonists have cardiovascular actions, independent of improving
glucose homeostasis, such as modulation of heart rate, blood
pressure, vascular tone and myocardial contractility. Importantly,
it appears that these agents may also have beneficial effects in the
setting of cardiovascular disease, eg, GLP-1 has been found to
exert cardioprotective effects in experimental models of dilated
cardiomyopathy, hypertensive heart failure and myocardial
infarction (MI). Preliminary data of clinical studies also indicated
that GLP-1 infusion may improve cardiac contractile function in
chronic heart failure (CHF) patients with and without diabetes,
and in MI patients after successful angioplasty [6].
It is of particular note that the transcription levels of BNP
decreased to baseline levels after treatment with the DPP-4
inhibitor, linagliptin (Figure 1). BNP is a biomarker of acute and
CHF also in renally compromised patients. Its levels are elevated
in patients with left ventricular dysfunction. Rapid changes in BNP
levels (up to 30% during the first 24 hours of treatment) reflect an
adequate response to CHF therapy [34].
In our study, brain-derived natriuretic peptide mRNA was
detected and was increased in the cardiac tissue of 5/6N rats and
decreased after short-term treatment of uremic rats with
linagliptin, suggesting an immediate improvement in cardiac
function after DPP-4 inhibition (Figure 1, Figure 4). In addition,
we have shown an inhibition of gene expression of profibrotic
factors TGF-b1, TIMP-1, Col3a1 and Col3a1 in the uremic rat
heart after DPP-4 inhibitor treatment.
This is the first study showing that the DPP-4 inhibitor,
linagliptin, may exert positive effects on CHF in the setting of
uremia (Figure 4).
It is a clear study limitation that the treatment was pretty short.
This forced us to evaluate potential cardiac efficiasy in the 5/6
nephrectomy model based on biomarkers like osteopontin,
elevation of plasma GLP-1, cardiac expression of BNP mRNA
and cardiac mRNA of TGF-b1, TIMP-1, Col1a1 as well as
Col3a1. A further limitation of this study is the fact that functional
readouts of heart function like echocardiography were not
performed in the current study. Our study should stimulate
studies aiming to analyses more longterm treatment effects and the
potential translation of this treatment into improvement of
mortality in this model of uremic cardiomyopathy. The potential
antifibrotic effects of DPP-4 inhibitors could provide an additional
benefit for patients with CKD and heart diseases that very often
accompany T2D [35] and may provide new therapy options for
this class of drugs.
Additional research could also be undertaken to evaluate the
effects of the DPP-4 inhibitor linagliptin in 5/6 nephrectomized
rats with direct GLP-1 infusions, and to compare doses of
linagliptin with doses of GLP-1 infusions that lead to similar
plasma concentrations. Such research could determine whether
linagliptin, in addition to its GLP-1 elevating effect, blocks the
degradation of other DPP-4 substrates with potential cardiac
targets. In addition, research should be undertaken to investigate
whether a combination of DDP-4 inhibitors and GLP-1 agonists
potentiate cardiac efficacy. This has not yet been determined even
in non-uremic cardiomyopathy models.
The non-renally eliminated DPP-4 inhibitor, linagliptin, has
been shown in this rat model to be safe in the CRF setting.
Linagliptin markedly increased plasma GLP-1 concentrations in
uremic rats and decreased gene expression of BNP, a marker of
left ventricular dysfunction, as well as the fibrotic markers TGF-b,
TIMP-1, Col 1a1 and Col 3a1 in uremic rat heart.
Further investigation addressing long-term DPP-4 inhibition in
the uremic rat heart is warranted to confirm possible new
therapeutic applications for the treatment of CHF.
Materials and Methods
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Figure 3. Gene expression of fibrosis markers in uremic rat
heart. Uremic condition led to a significant increase in gene expression
of profibrotic factors TGF-b1, TIMP-1, Col1a1 and Col3a1 in the 5/6
nephrectomized rats compared with corresponding sham-operated
rats. Linagliptin at a dose of 7 mmol/kg significantly inhibited mRNA
expression of profibrotic factors TGF-b1, TIMP-1, Col1a1 and Col3a1i n
uremic rat heart. Values are given in mean 6 SEM. N=7 sham-operated
rats, 5 5/6N rats, and 12 5/6N linagliptin-treated rats. *p,0.05;
***p,0.001.
doi:10.1371/journal.pone.0027861.g003
Figure 4. Influence of DPP-4 inhibition on cardiac impairment
in the setting of uremia.
doi:10.1371/journal.pone.0027861.g004
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Gesundheit und Soziales (LAGeSo, Turmstr. 2l, D-10559 Berlin,
Germany), permit number: G0366/08. All surgery was performed
under inhalation anesthesia with isoflurane, and all efforts were
made to minimize suffering.
Experimental design
Rats in which two-thirds of the left kidney were surgically
eliminated after previous right nephrectomy (5/6-nephrectomized
[5/6N] rats) were randomly allocated into four groups (N=8–13
rats per group) according to the following oral pretreatment:
linagliptin 0.5 mmol/kg/day corresponding to 0.24 mg/kg/day,
linagliptin 7 mmol/kg/day (3.3 mg/kg/day), sitagliptin 7 mmol/
kg/day (2.85 mg/kg/day), alogliptin 7 mmol/kg/day (2.34 mg/
kg/day); all calculations based on the free bases. The 0.5-mmol/kg
dose of linagliptin was selected as being the theoretical AUC
equivalent to the 5-mg dose used in humans. Sham-operated rats
were divided into four control groups (N=5–6 rats per group) in
the same manner.
Commencing at 8 weeks after surgery, substances were
administered once daily via oral gavage for 4 consecutive days.
On the fourth day of treatment, blood samples were collected from
the tail vein into ethylenediaminetetraacetic acid (EDTA)-coated
vials at 0.5, 1, 2, 4, 6, 10, 24, 48 and 72 h after administration of
the substance (Figure 5).
After centrifugation, plasma samples were stored at –20uC until
bioanalytical measurement. After the last blood sampling, animals
were sacrificed and kidneys were harvested and snap frozen in
liquid nitrogen.
Studies of kidney function included measurements of serum and
urine creatinine, glomerular filtration rate (GFR) and cystatin C at
8 weeks after surgery.
Animal surgery
Animal procedures were approved by the local authorities and
complied with the German Animal Protection Act. Male Wistar
rats (250–290 g; Charles River Laboratories, Sulzfeld, Germany)
were housed under standardized conditions with water and food
ad libitum. All procedures were performed under inhalation
anesthesia with isoflurane.
Chronic renal failure was initiated by a two-step 5/6
nephrectomy as previously described [36,37]. Briefly, a right
kidney was exposed via laparotomy and removed after ligation of
the renal pedicle. After a 2-week recovery period, the left kidney
was procured and lower and upper poles were surgically removed
in such a way that one-third of the left kidney mass remained.
Sham-operated rats underwent the same operations, but kidneys
were only mobilized instead of being removed. After recovery
from anesthesia, animals were transferred to the housing facility
and monitored until sacrifice. Body weight and urine output were
measured together with blood sampling at Week 8 after surgery.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the city of Berlin, Germany (Landesamt fu ¨r
Gesundheit und Soziales (LAGeSo, Turmstr. 2l, D-10559 Berlin,
Germany), permit number: G0366/08. All surgery was performed
under inhalation anesthesia with isoflurane, and all efforts were
made to minimize suffering.
Renal function tests
Induction of CRF by 5/6 nephrectomy was confirmed by
measuring creatinine clearance and plasma cystatin C as markers
of glomerular filtration. Creatinine concentration was measured
by the Jaffe colorimetric method. Creatinine clearance was
estimated as described previously [36]. Plasma concentrations of
b2-microglobulin, neutrophil gelatinase-associated lipocalin
(NGAL) and osteopontin were measured by automated immuno-
assays (Rules-Based Medicine, Inc., Austin, Texas) for the
assessment of tubular function.
Cardiac histology. Tissue samples were all embedded in
paraffin, cut into 3 mm and 1 mm sections and subjected to Sirius
Red, HE and Elastica-van Gieson staining. Cardiac morphology
(interstitial fibrosis, myocyte diameter) was analyzed using a
computer-aided image analysis system (for details see: 26, 27, 28).
Briefly, interstitial fibrosis was evaluated by estimating the
relationship of the total section area to fibrotic section area. We
analyzed 25 sections per animal. The myocyte diameter was
investigated in 1 mm sections after HE staining exactly as
described previously (26,27,28). We analyzed at least 100 mycytes
per animal.
Quantitative real-time PCR
Total RNA was extracted from 50 mg snap-frozen tissue by
homogenization in peqGold Trifast reagent (Peqlab). Residual
genomic DNA was removed with Turbo DNAse (Applied
Biosystems). The RNA concentration and purity were assayed
by spectrophotometry. First-strand cDNA synthesis was performed
with random hexamer primer and 1 mg RNA using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems) according
to the manufacturer’s instruction. (For further detail see Vinon-
Zellweger et al [38].)
Sequences from the Ensemble database and the online available
Primer3 software [39] were used to create specific, intron-
spanning primers for the target genes. Primer pairs were proved
for gene-specific amplification and the absence of single nucleotide
Figure 5. Active GLP-1 levels in uremic vs sham animals. The uremic situation resulted in a significant increase of GLP-1 AUC in 5/6N rats
compared with controls. Linagliptin (7 mmol/kg) was administered daily for 4 days. Following the last dose, plasma was taken after the time points
indicated and active GLP-1 was detected. Values are given as mean 6 SEM. N=5 sham-operated, and 8-12 rats for 5/6N.
doi:10.1371/journal.pone.0027861.g005
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Synthesized primers were obtained from Sigma-AldrichH.
A total of 10 ng cDNA in 5 ml was normally used as template
for amplification. An additional 0.5 ml of each primer (5 pmol) and
12.5 ml of Power SYBR Green PCR Master Mix (Applied
Biosystems) were added and diluted with water to a volume of
25 ml. The PCR was performed on an Mx3000P thermal cycler
(Stratagene). Reaction conditions were 95uC for 10 min, 40 cycles
at 95uC for 15 sec, and 60uC for 60 sec, followed by an
examination of the melting curve. All samples were analyzed in
triplicate. The amplification efficiency of every reaction was
checked with the linear regression method [26]. Expression of the
gene of interest was divided by the housekeeping gene,
glyceraldehyde-3-phosphate dehydrogenase, and expressed as
fold-change compared with the corresponding sham-operated rats
group.
Plasma DPP-4 activity and GLP-1 measurements
Blood samples were drawn from the rat retrobulbal venous
plexus under isoflurane anesthesia at serial time points immedi-
ately before pretreatment and at various time points after the
treatment (as described above) up to 72 h postdose. EDTA plasma
was frozen for ex vivo measurement of DPP-4 activity. A 20 ml
volume of EDTA plasma was diluted with 30 ml of DPP-4 assay
buffer (100 mM Tris, 100 mM NaCl, adjusted to pH 7.8 with
HCl) and mixed with 50 ml substrate (final concentration 100 mM
H-Ala-Pro-7-amido-4-trifluoromethylcoumarin (AlaPro-AFC) was
from Bachem) (200 mM stock solution in DMF, diluted 1:1000
with water). The plate was then incubated at room temperature
for 10 min and fluorescence of the wells was determined using a
Wallac Victor
TM 1420 Multilabel Counter, at an excitation
wavelength of 405 nm and an emission wavelength of 535 nm.
Active (uncleaved, 7–36 amide or 7–37) GLP-1 was detected
using the commercially available Multi-Array Assay System
(K150JWC) from Meso Scale Discovery following the instructions
of the supplier. This antibody only detects active GLP-1 (7–36
amide or 7–37 GLP-1) but not cleaved and inactive GLP- 1 (9–36
amide or 9–37 GLP-1).
Bioanalysis and pharmacokinetic evaluation
Plasma concentrations of linagliptin, sitagliptin and alogliptin
were determined by high performance liquid chromatography
coupled to tandem mass spectrometry (HPLC-MS/MS) using
solid phase extraction for sample preparation with a lower limit of
quantification of 0.100 nmol/l for linagliptin and 0.250 nmol/l for
sitagliptin and alogliptin. Linagliptin, sitagliptin and alogliptin
were analyzed by HPLC-MS/MS assays using [13C3] linagliptin,
sitagliptin and alogliptin as internal standards for linagliptin,
sitagliptin and alogliptin, respectively. The assays comprise sample
clean-up by solid phase extraction (SPE) on SPEC MP3 96-well
extraction plates for linagliptin and Focus 96-well extraction plates
for sitagliptin and alogliptin. Chromatography for all assays was
achieved on a Phenomenex Luna Phenyl-Hexyl 100A, 3 mm,
5062 mm analytical HPLC column with gradient elution. The
analytes were detected and quantified by HPLC-MS/MS using
electrospray ionization in the positive ion mode.
Pharmacokinetic analysis was performed using non-compart-
mental methods with ToxKin V 3.5 (LogicaCMG ITS AG,
Switzerland). The linear trapezoidal rule was used for AUC
calculation. Theterminal half-life (t(1/2))wascalculatedast(1/2) =
ln2/l(z) with the terminal elimination rate constant l(z) as slope of
the logarithmic-linear regression line lnC(t) = lnC(0 h) – l(z)6to f
two or three data points in the terminal phase. Extrapolated
AUC(rest, tz-‘) was calculated according to Aronson et al [40],
using the calculated concentration and time (t(z)) of the last
measurable data point.
Statistics
For PCR analysis, means 6 SEM were compared using the
two-tailed Student’s t-test for two groups and one-way analysis of
variance with paired comparisons for more than two groups.
Correlation analysis was performed using Spearman’s rank
correlation test. P-values of less than 0.05 were considered
significant. These statistical tests were performed using SPSS
10.0 for Windows (SPSS Inc., Chicago, IL, USA). For AUC
determinations, statistical comparison between sham and 5/6
nephrectomy was done by a one-factorial analysis of variance
(ANOVA) with heteroscedastic variances. For kidney function
analysis before and after drug administration for each parameter
the values were analyzed separately using an analysis of variance
for repeated measurements, with factors experimental group and
time as fixed effects. The values belonging to the same animal are
modeled as repeated measurements assuming an unstructured
covariance matrix.
Analysis of kidney function parameters before and after
compound administration
For each parameter, the log10-transformed values were
analyzed separately using an ANOVA for repeated measurements
with factors for experimental group and time as fixed effects. The
log10-transformed values belonging to the same animal are
modeled as repeated measurements assuming an unstructured
covariance matrix. These statistical analyses were carried out with
the software product SAS (SAS Institute, Cary, NC USA), version
9.2.
Acknowledgments
Editorial support was provided by Envision Ltd. We are grateful to Dr. C.
Ittrich for performing statistical analysis of the data and to Katja Thode for
technical assistance.
Author Contributions
Conceived and designed the experiments: TK BH. Performed the
experiments: LC KVW JR MA SH HF FR. Analyzed the data: LC TK
BH. Contributed reagents/materials/analysis tools: LC KVW JR MA SH
HF FR. Wrote the paper: LC TK BH.
References
1. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, et al. (2005) Chronic kidney
disease and the risk for cardiovascular disease, renal replacement, and death in the
United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489–495.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney
disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med 351: 1296–1305.
3. Tonelli M,Wiebe N, Culleton B, House A, Rabbat C, et al.(2006) Chronickidney
disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034–2047.
4. Ossum A, van Deurs U, Engstrom T, Jensen JS, Treiman M (2009) The
cardioprotective and inotropic components of the postconditioning effects of
GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 60: 411–417.
5. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, et al. (2011) Risk
of cardiovascular disease events in patients with type 2 diabetes prescribed the
glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other
glucose-lowering therapies: a retrospective analysis of the LifeLink database.
Diabetes Care 34: 90–95.
DPP-4 Inhibitors in Uremic Cardiomyopathy
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e278616. Grieve DJ, Cassidy RS, Green BD (2009) Emerging cardiovascular actions of the
incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond
glycaemic control? Br J Pharmacol 157: 1340–1351.
7. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, et al. (2005)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of
dipeptidyl peptidase IV, in healthy subjects: results from two randomized,
double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol
Ther 78: 675–688.
8. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, et al. (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of
sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized,
placebo-controlled study in healthy male volunteers. Clin Ther 28: 55–72.
9. Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagonlike peptide I
(7-37) actions on endocrine pancreas. Diabetes 38: 338–342.
10. Scheen AJ (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes
Obes Metab 12: 648–658.
11. Shvarts V (2008) [New avenues for pharmacotherapy of type 2 diabetes
mellitus]. Klin Med (Mosk) 86: 12–17.
12. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K (2010)
The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor,
linagliptin, in humans. Drug Metab Dispos 38: 667–678.
13. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, et al. (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of
linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Diabetes Obes Metab 11: 786–794.
14. Yan X, Sano M, Lu L, Wang W, Zhang Q, et al. (2010) Plasma concentrations
of osteopontin, but not thrombin-cleaved osteopontin, are associated with the
presence and severity of nephropathy and coronary artery disease in patients
with type 2 diabetes mellitus. Cardiovasc Diabetol 9: 70.
15. Kujal P, Vernerova Z (2008) [5/6 nephrectomy as an experimental model of
chronic renal failure and adaptation to reduced nephron number]. Cesk Fysiol
57: 104–109.
16. Horiba N, Masuda S, Takeuchi A, Saito H, Okuda M, et al. (2004) Gene
expression variance based on random sequencing in rat remnant kidney. Kidney
Int 66: 29–45.
17. Masuda S (2003) Functional characteristics and pharmacokinetic significance of
kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the
urinary excretion of anionic drugs. Drug Metab Pharmacokinet 18: 91–103.
18. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, et al. (2009)
Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of
diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using
wild-type and DPP4-deficient rats. J Endocrinol 200: 53–61.
19. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, et al. (2007) Cystatin
C and estimates of renal function: searching for a better measure of kidney
function in diabetic patients. Clin Chem 53: 480–488.
20. Rigalleau V, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, et al. (2008)
Cystatin C improves the diagnosis and stratification of chronic kidney disease,
and the estimation of glomerular filtration rate in diabetes. Diabetes Metab 34:
482–489.
21. Willems D, Wolff F, Mekhali F, Gillet C (2009) Cystatin C for early detection of
renal impairment in diabetes. Clin Biochem 42: 108–110.
22. Amann K, Breitbach M, Ritz E, Mall G (1998) Myocyte/capillary mismatch in
the heart of uremic patients. J Am Soc Nephrol 9: 1018–1022.
23. Mall G, Huther W, Schneider J, Lundin P, Ritz E (1990) Diffuse
intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5:
39–44.
24. Tyralla K, Amann K (2003) Morphology of the heart and arteries in renal
failure. Kidney Int Suppl. pp S80–83.
25. Lindsay MM, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular
diastolic dysfunction and fibrosis in hypertension. Hypertension 40: 136–141.
26. Rabkin R, Awwad I, Chen Y, Ashley EA, Sun D, et al. (2008) Low-dose growth
hormone is cardioprotective in uremia. J Am Soc Nephrol 19: 1774–1783.
27. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, et al. (2009)
Spironolactone attenuates experimental uremic cardiomyopathy by antagoniz-
ing marinobufagenin. Hypertension 54: 1313–1320.
28. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC, Jr. (2007)
Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation.
Am J Physiol Regul Integr Comp Physiol 292: R897–901.
29. Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer
of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453–1464.
30. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU (2005) Identification of target
genes of the transcription factor HNF1beta and HNF1alpha in a human
embryonic kidney cell line. Biochim Biophys Acta 1731: 179–190.
31. Ku HC, Chen WP, Su MJ (2010) GLP-1 signaling preserves cardiac function in
endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch
Pharmacol 382: 463–474.
32. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, et al. (2004) Secretion,
degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory
polypeptide in patients with chronic renal insufficiency and healthy control
subjects. Diabetes 53: 654–662.
33. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type
2 diabetes: systematic review and meta-analysis. Jama 298: 194–206.
34. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, et al. (2009) BNP-guided vs
symptom-guided heart failure therapy: the Trial of Intensified vs Standard
Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-
CHF) randomized trial. Jama 301: 383–392.
35. National Institute of Diabetes and Digestive and Kidney Diseases US Renal
Data Systems: USRDS 2011 annual data report: Atlas of End Stage Renal
Disease in the United States. National Institutes of Health, Bethesda, Maryland,
USA; http://www.usrds.org/adr.aspx.
36. Kalk P, Eggert B, Relle K, Godes M, Heiden S, et al. (2007) The adenosine A1
receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6
nephrectomy without affecting blood pressure. Br J Pharmacol 151: 1025–1032.
37. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, et al. (2006) NO-
independent activation of soluble guanylate cyclase prevents disease progression
in rats with 5/6 nephrectomy. Br J Pharmacol 148: 853–859.
38. Vignon-Zellweger N, Relle K, Kienlen E, Alter M, Seider P, et al. (2011)
Endothelin-1 overexpression restores diastolic function in eNOS knockout mice.
J Hypertens 29: 961–970.
39. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 132: 365–386.
40. Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Standardization of symbols
in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7.
DPP-4 Inhibitors in Uremic Cardiomyopathy
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27861